Loading clinical trials...
Loading clinical trials...
Efficacy of Tuvusertib in Recurrent IDH Mutant Astrocytoma With ATRX Mutation, a Phase II Prospective Trial.
Conditions
Interventions
Tuvusertib
Locations
10
Spain
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Barcelona, Spain
Hospital Universitario de Cruces
Barakaldo, Bizkaia, Spain
Hospital Universitario Virgen de las Nieves
Granada, Granada, Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain
Start Date
December 19, 2025
Primary Completion Date
September 1, 2028
Completion Date
September 1, 2028
Last Updated
April 2, 2026
NCT04065776
NCT02800486
NCT05789394
NCT06809322
NCT06860594
NCT05839379
Lead Sponsor
Grupo Español de Investigación en Neurooncología
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions